Rain could lead to more mosquitoes in Minnesota, experts say
Could the number of mosquitoes still increase in Minnesota this summer?
Could the number of mosquitoes still increase in Minnesota this summer?
As Minnesotans prepare for backyard barbeques, an uninvited guest is making a strong comeback: mosquitoes.
Experts say cooler weather and low river levels could be responsible for our slow start to the mosquito season.
"Right now, mosquitos are well below average this time of year. But they're starting to creep back up," said Alex Carlson, with the Metropolitan Mosquito Control District.
Carlson says this year was the first time in three years we did not see a significant emergence of spring mosquitoes in May and early June. Rainfall expected this week could lead to significant increase. Specifically, a common summer nuisance, "cattail mosquitoes."
"They are very aggressive. They love to feed on us, but fortunately they typically don't carry disease just annoying and cause big red welts," Carlson said.
In response, aerial and ground treatments will continue as MMCD jump back into their busy season.
"We're going to be very busy next couple of days trying to get helicopters and getting staff out to do our treatments now, so we can knock down the population before the 4th of July," Carlson said.
Avoiding bites isn't just what officials do, it starts before you leave your house.
Mosquito control experts say there are some easy steps you can follow:
Make sure not to skip bug spray. Avoid dusk and dawn, when mosquitoes are most active. Skip sweet scents.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Iowa weather: One more day in the 80s before the Summer heat comes roaring back
Iowa weather: One more day in the 80s before the Summer heat comes roaring back
Yahoo
14 minutes ago
- Yahoo
One in four US adults with diabetes used a GLP-1 drug last year, survey finds
By Bhanvi Satija (Reuters) -More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the U.S. Centers for Disease Control and Prevention said on Thursday. The wildly popular and effective GLP-1 drugs Mounjaro from Eli Lilly and Ozempic from Novo Nordisk are approved in the United States for treating type 2 diabetes. They are sold as Zepbound and Wegovy, respectively, for weight loss and are being tested for other conditions. Use of the injectable drugs was highest among adults with diabetes aged 50–64 at 33.3%, reflecting the more significant disease burden in this group, the report said. A quarter or 25.3% of adults with diabetes aged 18 to 34 reported using a GLP-1 drug, while the adoption rate was 20.8% among those 65 and older. The data are from a nationally representative annual survey of U.S. adults aged 18 and older that was conducted in person and with follow-up by phone in 2024. In 2024, for the first time, participants in the annual survey who had diabetes were asked if they were using the Lilly or Novo blockbusters or other GLP-1 drugs to lower blood sugar or lose weight. The drugs mimic the activity of a hormone that regulates blood sugar levels, slows digestion and helps people feel full for longer. Drugmakers Lilly and Novo have faced criticism about the cost of the treatments, which carry a list price of about $1,000 for a month's supply. Roughly 31% of survey participants who reported using insulin also reported using GLP-1 drugs, as did about 28% of patients who were using oral drugs to control their blood sugar, according to the report, indicating that these treatments are being integrated into combination regimens. Hispanic adults with diabetes had the highest rate of GLP-1 use, at 31.3%, followed by Black non-Hispanic and White non-Hispanic adults, at 26.5% and 26.2%, respectively, the survey found. Only 12.1% of Asian non-Hispanic adults with diabetes used the drugs, which may reflect disparities in access or adoption of the therapies. Solve the daily Crossword
Yahoo
42 minutes ago
- Yahoo
Cowboys owner Jerry Jones reveals decade-long battle with Stage 4 cancer diagnosis
Dallas Cowboys owner Jerry Jones credited an experimental trial drug for successfully treating advanced melanoma as he disclosed his cancer diagnosis publicly for the first time. Jones revealed his illness in a documentary series, 'America's Team: The Gambler and His Cowboys,' which will debut on Netflix next week. The 82-year-old Jones then told The Dallas Morning News how he was initially diagnosed in June 2010 and underwent two surgeries on his lung and two on his lymph nodes over the next 10 years after skin cancer cells metastasized to other parts of his body. 'Well, you don't like to think about your mortality, but I was so fortunate to have some great people that sent me in the right direction,' Jones said after practice on Wednesday. 'I got to be part of a trial that was propitious. It really worked. It's called PD-1 (therapy), and it really, really, really worked.' First-year Cowboys coach Brian Schottenheimer described Jones' fight with cancer as an 'amazing story' and praised him for going public. 'I'm glad that Jerry shared it, just because I think it gives people hope,' Schottenheimer said Wednesday. 'It gives people the strength to say … 'Hey, you can beat this.'' Schottenheimer, 51, used his last news conference of the Cowboys' nearly monthlong stay in Southern California to talk about his own cancer diagnosis. He underwent surgery in 2003 for thyroid cancer at the Mayo Clinic in Rochester, Minnesota. Then-Washington Commanders owner Dan Snyder helped arrange Schottenheimer's treatment two years after firing his father, Marty Schottenheimer, as coach. Brian Schottenheimer was Washington's quarterbacks coach during the 2001 season, the same year Snyder himself was treated for thyroid cancer. 'It doesn't discriminate against anybody,' Schottenheimer said. 'And mine was certainly less serious, but I was 28 when I was diagnosed with thyroid cancer. Nothing like Stage 4, nothing like what Jerry and other people have to go through. But you hear that word 'cancer,' and it scares the hell out of you.'
